Wegovy does more than suppress appetite — here is what the evidence says

If your main goal is weight loss, does the extra biology matter?

It depends on what is driving your weight. Appetite suppression is doing real work: Wegovy lowers the hunger signals that originate in the hypothalamus, and it slows gastric emptying so meals feel satisfying for longer. If you want to understand whether and how Wegovy suppresses appetite, that is worth reading before you consider the broader metabolic picture. If you want to understand how quickly that appetite effect kicks in, the timeline of appetite suppression on Wegovy is worth reading before you start.

But semaglutide also acts on GLP-1 receptors in the pancreas, raising insulin secretion in response to meals and lowering glucagon. Blood sugar stabilises. For people with prediabetes or insulin resistance (both common alongside obesity) that metabolic effect reinforces weight loss rather than simply adding to it: steadier glucose means fewer energy crashes, which means fewer episodes of reactive eating. So even if your only goal is losing weight, the biology underneath is doing more than one thing.

In the STEP 1 trial, published in the New England Journal of Medicine, adults without diabetes on 2.4 mg semaglutide lost around 15% of body weight on average over 68 weeks. Much of that came from reduced intake, but improved insulin sensitivity contributed to how that loss was maintained.

What the cardiovascular and liver evidence adds to the picture

In 2024 the MHRA granted Wegovy a second UK licence: reducing the risk of serious cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity or overweight who already have established heart disease. The SELECT trial, which enrolled over 17,000 participants, showed a roughly 20% reduction in major cardiovascular events compared with placebo, and crucially, that benefit was not fully explained by the amount of weight lost. Something else was happening. Researchers point to reduced inflammation, lower blood pressure and direct effects of semaglutide on cardiac and arterial tissue.

Then, on 3 July 2026, the MHRA conditionally approved Wegovy for MASH (metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease) in adults with moderate-to-advanced fibrosis. The government's announcement confirmed this as a separate licensed indication from weight management. That is a striking regulatory signal: a medicine originally approved because it suppresses appetite now holds three distinct UK licences.

If you have heart disease, fatty liver disease or significant metabolic risk, these approvals are directly relevant to a conversation with your prescriber, not just background colour.

Is Wegovy doing anything appetite alone cannot explain? The honest summary

Appetite suppression is the dominant effect for most people in most weeks. You eat less, you lose weight. Simple and genuine. But the full picture is more interesting. NHS guidance on semaglutide describes GLP-1 receptor agonism as acting across multiple systems: it reduces liver glucose output, improves beta-cell function, and has central effects on reward and food-preference circuitry that go beyond raw hunger levels. Some people on Wegovy report reduced interest in alcohol and compulsive eating behaviours, research into those effects is ongoing, and claims should be treated cautiously, but they are not groundless.

For a practical sense of what this means day to day, how appetite suppression on Wegovy actually feels covers the patient experience, while eating well on Wegovy addresses how to make the most of reduced hunger without losing muscle or missing key nutrients. The medicine does the metabolic work; diet and activity habits shape what that work produces.

A note on cost: if you are weighing whether Wegovy's broader benefits justify the private price, the cost of Wegovy in the UK page sets out what legitimate private treatment includes and what market prices look like since recent list-price changes. The Wegovy treatment overview covers eligibility, the titration schedule and how our prescribers review each case. When you are ready to find out whether Wegovy is right for you, checking your eligibility with our clinical team is the natural next step.